Hidden

Genital Herpes

MARKET POTENTIAL FOR AN INTRAVAGINAL RING FOR THE TREATMENT OF RECURRENT GENITAL HERPES

According to the CDC, about 21% of women in the Unites States (i.e. 33 million) are infected with the HSV-2 virus which causes genital herpes. About 20% of those women are symptomatic (6.6 million). Note that asymptomatic women may also suffer from viral shedding and transmit the virus.

Genital herpes may cause painful genital ulcers, which are treated with antivirals such as acyclovir, famciclovir, and valacyclovir. Women that experience more than 2 outbreaks a year usually take these oral antivirals every day. These drugs are also used for the prevention of transmission of genital herpes to uninfected partners.

Auritec Pharmaceuticals has formulated an Acyclovir intravaginal ring which may improve compliance and ease of use in women suffering from genital herpes. This IVR has been tested in vitro and in vivo and has shown sustained-release in a first-in-human clinical trial. It is being further developed for a first-in-human dose-escalation clinical trial.

The global herpes treatment market is forecast to grow to over $4 billion by 2017.